Clarity Receives US FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer

0
34
Clarity Pharmaceuticals announced that the US FDA has granted fast track designation for 64Cu-SAR-bisPSMA for positron emission tomography imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions.
[Clarity Pharmaceuticals]
Press Release